(Q40707640)

English

Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C.

scientific article published on 21 March 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C. (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

1 reference

based on heuristic

inferred from title

2

object named as

Naoya Sakamoto

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Yasuhito Tanaka

14

object named as

Yasuhito Tanaka

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

author name string

Mina Nakagawa

1

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Takako Watanabe

3

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Yuki Nishimura-Sakurai

4

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Izumi Onozuka

5

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Seishin Azuma

6

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Sei Kakinuma

7

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Sayuri Nitta

8

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Kei Kiyohashi

9

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Akiko Kusano-Kitazume

10

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Miyako Murakawa

11

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Kohei Yoshino

12

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Yasuhiro Itsui

13

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Masashi Mizokami

15

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Mamoru Watanabe

16

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Ochanomizu-Liver Conference Study Group

17

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

publication date

21 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Hepatology international

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

153-161

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Epidemiology of hepatitis C

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review.

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks.

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Telaprevir for retreatment of HCV infection

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

ITPA gene variant protects against anemia induced by pegylated interferon-α and ribavirin therapy for Japanese patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Hematologic side effects of interferon and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Individual variation in inosine triphosphate accumulation in human erythrocytes

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Ribavirin treatment for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

A pilot study of ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9363-6

21 January 2018

New therapeutic approaches to hepatitis C virus

1 reference

https://pubmed.ncbi.nlm.nih.gov/26201629

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular mechanisms of action of ribavirin

1 reference

https://pubmed.ncbi.nlm.nih.gov/26201629

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Individual variation in inosine triphosphate accumulation in human erythrocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/26201629

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiviral strategies in hepatitis C virus infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/26201629

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12072-012-9363-6

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40707640&oldid=2203909588"